Skip to main content

Vyvgart Disease Interactions

There are 2 disease interactions with Vyvgart (efgartigimod alfa).

Moderate

Efgartigimod alfa (applies to Vyvgart) infection

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Efgartigimod alfa may increase the risk of infection. Clinical studies have shown patients receiving efgartigimod alfa had below normal levels of white blood cell counts, lymphocytes, and neutrophils compared to placebo. Treatment with efgartigimod alfa should be delayed in patients with an active infection until the infection is resolved. During treatment, monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding efgartigimod alfa until the infection has resolved.

References

  1. (2022) "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc.
Moderate

Efgartigimod alfa (applies to Vyvgart) vaccinations

Moderate Potential Hazard, Moderate plausibility.

Vaccination with live-attenuated or live vaccines is not recommended during treatment with efgartigimod alfa because efgartigimod alfa causes a reduction in IgG levels. It is recommended to be up-to-date with all required immunizations, as recommended by current immunization guidelines, before initiating a new treatment cycle.

References

  1. (2022) "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc.

Vyvgart drug interactions

There are 282 drug interactions with Vyvgart (efgartigimod alfa).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.